Sikiric is named on BPC-157-related patent applications dating back to at least 1989, and Croatian government records list Predrag Sikiric as an owner of PharmaCotherapia, the company that sponsored the Tijuana trial
Phase Tirz escalation 1 Weeks 5-8 Tirzepatide 5.0 mg/week Cagrilintide Not started Notes Continue tirzepatide alone
Clinical Response: Doctors might change the dose based on how well the patient is doing
and 3-numerous confluent changes subcategorized into: (a) the hemorrhagic zone, (b) edema, (c) the loss of neurons, (d) vacuoles, and (e) the loss of spinal column tracts [3]
Final Takeaway GHK-Cu is not a magic answer but it is a genuinely promising, research-backed piece of a larger puzzle that most people with hair loss have never been shown
Patient Goals and Treatment Intent Most patients want to recover faster, optimize wellness, or help a musculoskeletal issue